Mineralys Therapeutics (MLYS) said Monday it started a $250 million underwritten public offering of shares.
Underwriters in the offering will have a 30-day option to buy up to an additional $37.5 million shares, according to the company.
Proceeds from the offering will be used for clinical development of lorundrostat as well as working capital and general corporate purposes, Mineralys added.
Shares of Mineralys Therapeutics were up more than 1% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.